These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33685969)

  • 21. Longitudinal outcomes of radiofrequency ablation versus surveillance endoscopy for Barrett's esophagus with low-grade dysplasia.
    Kahn A; Al-Qaisi M; Kommineni VT; Callaway JK; Boroff ES; Burdick GE; Lam-Himlin DM; Temkit M; Vela MF; Ramirez FC
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29036431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial).
    Phoa KN; Rosmolen WD; Weusten BLAM; Bisschops R; Schoon EJ; Das S; Ragunath K; Fullarton G; DiPietro M; Ravi N; Tijssen JGP; Dijkgraaf MGW; Bergman JJGHM;
    Gastrointest Endosc; 2017 Jul; 86(1):120-129.e2. PubMed ID: 27956164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiofrequency ablation for low-grade dysplasia in Barrett's esophagus.
    Nayna L; Emma W; Vani K
    Curr Opin Gastroenterol; 2016 Jul; 32(4):294-301. PubMed ID: 27070914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis.
    Orman ES; Li N; Shaheen NJ
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1245-55. PubMed ID: 23644385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simplified versus standard regimen for focal radiofrequency ablation of dysplastic Barrett's oesophagus: a multicentre randomised controlled trial.
    Pouw RE; Künzli HT; Bisschops R; Sondermeijer CM; Koch AD; Didden P; Gotink AW; Schoon EJ; Curvers WL; Bergman JJGHM; Weusten BLAM
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):566-574. PubMed ID: 29934224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia is Rare: Final Report From Ablation in Intestinal Metaplasia Containing Dysplasia Trial.
    Cotton CC; Wolf WA; Overholt BF; Li N; Lightdale CJ; Wolfsen HC; Pasricha S; Wang KK; Shaheen NJ;
    Gastroenterology; 2017 Sep; 153(3):681-688.e2. PubMed ID: 28579538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Outcomes Following Recurrence of Intestinal Metaplasia After Successful Treatment of Barrett's Esophagus With Radiofrequency Ablation.
    Guthikonda A; Cotton CC; Madanick RD; Spacek MB; Moist SE; Ferrell K; Dellon ES; Shaheen NJ
    Am J Gastroenterol; 2017 Jan; 112(1):87-94. PubMed ID: 27725648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients With Barrett's Esophagus and Confirmed Persistent Low-Grade Dysplasia Are at Increased Risk for Progression to Neoplasia.
    Duits LC; van der Wel MJ; Cotton CC; Phoa KN; Ten Kate FJW; Seldenrijk CA; Offerhaus GJA; Visser M; Meijer SL; Mallant-Hent RC; Krishnadath KK; Pouw RE; Tijssen JGP; Shaheen NJ; Bergman JJGHM
    Gastroenterology; 2017 Apr; 152(5):993-1001.e1. PubMed ID: 28012849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intestinal metaplasia recurs infrequently in patients successfully treated for Barrett's esophagus with radiofrequency ablation.
    Orman ES; Kim HP; Bulsiewicz WJ; Cotton CC; Dellon ES; Spacek MB; Chen X; Madanick RD; Pasricha S; Shaheen NJ
    Am J Gastroenterol; 2013 Feb; 108(2):187-95; quiz 196. PubMed ID: 23247578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for initial treatment response after circumferential radiofrequency ablation for Barrett's esophagus with early neoplasia: a prospective multicenter study.
    van Vilsteren FG; Alvarez Herrero L; Pouw RE; Schrijnders D; Sondermeijer CM; Bisschops R; Esteban JM; Meining A; Neuhaus H; Parra-Blanco A; Pech O; Ragunath K; Rembacken B; Schenk BE; Visser M; ten Kate FJ; Meijer SL; Reitsma JB; Weusten BL; Schoon EJ; Bergman JJ
    Endoscopy; 2013 Jul; 45(7):516-25. PubMed ID: 23580412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cryotherapy and Radiofrequency Ablation for Eradication of Barrett's Esophagus with Dysplasia or Intramucosal Cancer.
    Thota PN; Arora Z; Dumot JA; Falk G; Benjamin T; Goldblum J; Jang S; Lopez R; Vargo JJ
    Dig Dis Sci; 2018 May; 63(5):1311-1319. PubMed ID: 29524114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Durability of radiofrequency ablation for long-segment and ultralong-segment Barrett's esophagus over 10 years.
    Nguyen CL; Tovmassian D; Zhou M; Seyfi D; Gooley S; Falk GL
    Surg Endosc; 2024 Mar; 38(3):1239-1248. PubMed ID: 38092973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period.
    van Munster S; Nieuwenhuis E; Weusten BLAM; Alvarez Herrero L; Bogte A; Alkhalaf A; Schenk BE; Schoon EJ; Curvers W; Koch AD; van de Ven SEM; de Jonge PJF; Tang TJ; Nagengast WB; Peters FTM; Westerhof J; Houben MHMG; Bergman JJ; Pouw RE;
    Gut; 2022 Feb; 71(2):265-276. PubMed ID: 33753417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.
    Phoa KN; van Vilsteren FG; Weusten BL; Bisschops R; Schoon EJ; Ragunath K; Fullarton G; Di Pietro M; Ravi N; Visser M; Offerhaus GJ; Seldenrijk CA; Meijer SL; ten Kate FJ; Tijssen JG; Bergman JJ
    JAMA; 2014 Mar; 311(12):1209-17. PubMed ID: 24668102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective pilot trial of ablation of Barrett's esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system).
    Sharma VK; Kim HJ; Das A; Dean P; DePetris G; Fleischer DE
    Endoscopy; 2008 May; 40(5):380-7. PubMed ID: 18459074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of subsquamous high-grade dysplasia and adenocarcinoma after successful radiofrequency ablation of Barrett's esophagus.
    Titi M; Overhiser A; Ulusarac O; Falk GW; Chak A; Wang K; Sharma P
    Gastroenterology; 2012 Sep; 143(3):564-566.e1. PubMed ID: 22561053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistent confirmed low-grade dysplasia in Barrett's esophagus is a risk factor for progression to high-grade dysplasia and adenocarcinoma in a US Veterans cohort.
    Song KY; Henn AJ; Gravely AA; Mesa H; Sultan S; Shaheen NJ; Shaukat A; Hanson BJ
    Dis Esophagus; 2020 Mar; 33(2):. PubMed ID: 31274147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors that predict a poor response to radiofrequency ablation for Barrett's oesophagus with dysplasia.
    Tsoi EH; Cameron G; Williams R; Desmond P; Taylor A
    ANZ J Surg; 2020 Mar; 90(3):272-276. PubMed ID: 31970858
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.
    Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ;
    Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.